Newron Pharmaceuticals Announces AGM 2026 Results

Newron Pharmaceuticals S.p.A., a biopharmaceutical company based in Milan, Italy, announced the approval of all motions in the ordinary part of their AGM 2026. The meeting, held on April 23, 2026, resulted in the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, motions in the extraordinary part were not voted on due to an insufficient quorum.

Chris Martin, Chairman of the Board, expressed gratitude toward the shareholders and welcomed the new board members, while acknowledging the contributions of Patrick Langlois and Luca Benatti, who have stepped down.

Newron is dedicated to developing innovative CNS therapies, with lead compound evenamide in a Phase III program for treatment-resistant schizophrenia. Their marketed product Xadago® is used for Parkinson's disease treatment in multiple countries.